Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma

Leuk Lymphoma. 2002 Nov;43(11):2145-9. doi: 10.1080/1042819021000032971.


Targeted therapy with conjugated and unconjugated monoclonal antibodies for non-Hodgkin's lymphoma has revolutionized the approach to this disease. The efficacy and low toxicity of these agents have allowed introduction of this strategy in the early stages of therapy. Longer follow-up is needed before validating the safety of these agents. Since monoclonal antibodies are being given as front-line therapy, it is important to identify all potential adverse events. We report a case of secondary acute myelogenous leukemia (AML) with 11q23 cytogenetic abnormality and mixed lymphoid leukemia (MLL) gene expression in a patient treated with Y90 labeled anti-CD20 antibody (Zevalin). The patient was not exposed to topoisomerase II inhibitors. Our observations suggest a relationship between 11q23 leukemia and radioimmunotherapy (RAIT) and further studies are needed.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens, CD20 / immunology
  • Chromosomes, Human, Pair 11 / radiation effects
  • DNA-Binding Proteins / genetics*
  • Female
  • Gene Rearrangement / radiation effects
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Immunoconjugates / adverse effects
  • Immunoconjugates / therapeutic use
  • Leukemia, Myeloid, Acute / etiology
  • Leukemia, Myeloid, Acute / genetics*
  • Lymphoma, Non-Hodgkin / pathology
  • Lymphoma, Non-Hodgkin / radiotherapy*
  • Myeloid-Lymphoid Leukemia Protein
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / genetics*
  • Proto-Oncogenes*
  • Radioimmunotherapy / adverse effects*
  • Transcription Factors*
  • Yttrium Radioisotopes / adverse effects
  • Yttrium Radioisotopes / therapeutic use


  • Antigens, CD20
  • DNA-Binding Proteins
  • Immunoconjugates
  • KMT2A protein, human
  • Transcription Factors
  • Yttrium Radioisotopes
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase